Notice of AGM
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 18 November 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that the AGM of the Company will be held at 16 Columbus Walk, Brigantine Place, Cardiff, CF10 4BY on Friday 11 December 2026 at 10:30 a.m. (GMT).
The full Notice of AGM has been posted to shareholders who have not consented to receive electronic communications and is available on the Company website here: https://investors.renalytix.com/documents/.
As announced on 14 September 2026, the Company has extended its accounting reference date to 31 December 2026. As a result, the Company will publish audited accounts for the 18 month period ending 31 December 2026 by 30 June 2027, at which time an Annual General Meeting will be convened to lay them before shareholders.
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.
Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.